HER2-positive breast cancer trial using ctDNA to guide treatment
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a personalized treatment plan for HER2-positive breast cancer that has spread. It uses a blood test to track cancer DNA and adjust therapy, including treatments that may help prevent cancer from reaching the brain. The goal is to achieve long-term remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with HER2-positive (3+ score) breast cancer that has spread to other parts of the body or cannot be removed by surgery.
- Your cancer must be stage IV when first diagnosed, meaning it has spread at diagnosis.
- You should be healthy enough for surgery, or likely to become operable after initial treatment.
- You must have not received any prior anti-HER2 therapy or other cancer treatment for breast cancer.
- Your overall health status must be good (ECOG score 0 or 1), and your organs must work well (blood counts, liver, kidney function within limits).
- If you can become pregnant or get someone pregnant, you must agree to use effective contraception during and after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different treatments tailored to your cancer's biology. It aims to find which therapy might work best for you, potentially improving outcomes. You'd receive one of the study drugs, with close monitoring and support.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
This study tests a personalized treatment approach for HER2-positive breast cancer. It uses regular monitoring of your tumor to adjust the treatment before surgery, aiming to improve results. It might help you by tailoring therapy to your cancer's response.
This study tests a personalized approach for early-stage breast cancer that is HER2-positive or triple-negative. The goal is to adjust your treatment based on how well the cancer responds to chemotherapy before surgery, so you get the right amount of radiation therapy—no more, no less.
This Phase 2 study tests a personalized immune-therapy vaccine made from your immune cells, given with weekly paclitaxel and HER2-targeted antibodies (trastuzumab and pertuzumab). It aims to improve treatment outcomes for people with HER2-positive breast cancer before standard local treatment (like surgery and radiation).
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.